Meeting
2018 Gastrointestinal Cancers Symposium
ClarIDHy: A phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation.
Authors
Ghassan K. Abou-Alfa
Memorial Sloan Kettering Cancer Center/ Weill Cornell Medical College, New York, NY
Ghassan K. Abou-Alfa , Juan W. Valle , Robin Kate Kelley , Lipika Goyal , Rachna T. Shroff , Milind M. Javle , Mitesh J. Borad , James M. Cleary , Anthony B. El-Khoueiry , Johanna C. Bendell , Teresa Mercade Macarulla , Arndt Vogel , Christopher Korth , Liewen Jiang , Camelia Gliser , Bin Wu , Samuel V. Agresta , Shuchi Sumant Pandya , Andrew X. Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02989857
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr TPS545)
DOI
10.1200/JCO.2018.36.4_suppl.TPS545
Abstract #
TPS545
Poster Bd #
Q21
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
ClarIDHy: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation.
First Author: Maeve Aine Lowery
Poster
2020 Gastrointestinal Cancers Symposium
Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with mutant IDH1 advanced cholangiocarcinoma from the phase III ClarIDHy study.
First Author: Bin Fan
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Integration of molecular cancer classification and NGS to identify metastatic patients eligible for IDH inhibitors.
First Author: Pashtoon Murtaza Kasi
Poster
2018 ASCO Annual Meeting
AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation.
First Author: Eytan Stein